{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:31:19Z","timestamp":1788280279170,"version":"build-2803163510"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074002"],"award-info":[{"award-number":["82074002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274079"],"award-info":[{"award-number":["82274079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2019YFC1709405"],"award-info":[{"award-number":["2019YFC1709405"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","award":["2021SF-380"],"award-info":[{"award-number":["2021SF-380"]}],"id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.intimp.2023.110317","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T03:55:53Z","timestamp":1684295753000},"page":"110317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Membranous nephropathy: Mechanistic insights and therapeutic perspectives"],"prefix":"10.1016","volume":"120","author":[{"given":"Meng-Ru","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Long","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-7342","authenticated-orcid":false,"given":"Ying-Yong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110317_b0005","article-title":"Recent advances in clinical diagnosis and pharmacotherapy options of membranous nephropathy","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110317_b0010","doi-asserted-by":"crossref","first-page":"969930","DOI":"10.3389\/fphar.2022.969930","article-title":"Membranous nephropathy: Systems biology-based novel mechanism and traditional Chinese medicine therapy","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2017.34","article-title":"T cells and autoimmune kidney disease","volume":"13","author":"Su\u00e1rez-Fueyo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.intimp.2023.110317_b0020","doi-asserted-by":"crossref","first-page":"109412","DOI":"10.1016\/j.intimp.2022.109412","article-title":"Cytokines network in primary membranous nephropathy","volume":"113","author":"Zhao","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110317_b0025","doi-asserted-by":"crossref","first-page":"665629","DOI":"10.3389\/fimmu.2021.665629","article-title":"Helper T cells in idiopathic membranous nephropathy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"issue":"9337","key":"10.1016\/j.intimp.2023.110317_b0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","journal-title":"J. Formos. Med. Assoc"},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0040","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.kint.2015.11.032","article-title":"Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy","volume":"89","author":"Guerry","year":"2016","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0045","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.04321007","article-title":"Idiopathic membranous nephropathy: Diagnosis and treatment","volume":"3","author":"Fervenza","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/j.ajkd.2012.02.333","article-title":"Membranous nephropathy with renal salt wasting: Role of neurohumoral factors in sodium retention","volume":"60","author":"Hommos","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.intimp.2023.110317_b0055","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00424-017-2007-x","article-title":"A podocyte view of membranous nephropathy: From Heymann nephritis to the childhood human disease","volume":"469","author":"Ronco","year":"2017","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.intimp.2023.110317_b0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3389\/fimmu.2019.01809","article-title":"Immunological pathogenesis of membranous nephropathy: Focus on PLA2R1 and its role","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0065","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ki.2014.381","article-title":"Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies","volume":"87","author":"Vivarelli","year":"2015","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0075","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110317_b0080","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110317_b0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000507704","article-title":"Advances in pathogenesis of idiopathic membranous nephropathy","volume":"6","author":"Xu","year":"2020","journal-title":"Kidney Dis."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110317_b0095","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.kint.2019.10.022","article-title":"A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients","volume":"97","author":"Meyer-Schwesinger","year":"2020","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0100","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2023.110317_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8163298","article-title":"A novel insight into the role of PLA2R and THSD7A in membranous nephropathy","volume":"2021","author":"Zhang","year":"2021","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MNH.0000000000000459","article-title":"Unmet challenges in membranous nephropathy","volume":"28","author":"Salant","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"20","key":"10.1016\/j.intimp.2023.110317_b0115","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/jcm10040607","article-title":"Advances in membranous nephropathy","volume":"10","author":"Ronco","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0125","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1172\/JCI110793","article-title":"Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit","volume":"71","author":"Adler","year":"1983","journal-title":"J. Clin. Invest."},{"issue":"22","key":"10.1016\/j.intimp.2023.110317_b0135","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMoa1013792","article-title":"Early-childhood membranous nephropathy due to cationic bovine serum albumin","volume":"364","author":"Debiec","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0140","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1681\/ASN.2013030290","article-title":"Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: A need for tolerance induction therapy","volume":"25","author":"Debiec","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0145","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","article-title":"Immunopathogenesis of membranous nephropathy: An update","volume":"36","author":"Debiec","year":"2014","journal-title":"Semin. Immunopathol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0150","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI109987","article-title":"A new role for complement in experimental membranous nephropathy in rats","volume":"66","author":"Salant","year":"1980","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0155","first-page":"185","article-title":"Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats","volume":"135","author":"Baker","year":"1989","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0160","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ki.1991.242","article-title":"Elevated urinary excretion of the C5b\u20139 complex in membranous nephropathy","volume":"40","author":"Schulze","year":"1991","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.intimp.2023.110317_b0165","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ki.2010.34","article-title":"Membranous nephropathy: Recent travels and new roads ahead","volume":"77","author":"Beck","year":"2010","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000486552","article-title":"Mannose-binding lectin2 gene polymorphism and IgG4 in membranous nephropathy","volume":"139","author":"Costa","year":"2018","journal-title":"Nephron."},{"key":"10.1016\/j.intimp.2023.110317_b0175","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12026-016-8790-1","article-title":"IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: An inspiration from a cross-sectional study","volume":"64","author":"Yang","year":"2016","journal-title":"Immunol. Res."},{"issue":"12","key":"10.1016\/j.intimp.2023.110317_b0180","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1681\/ASN.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0185","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/art.30222","article-title":"The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL\/lpr mice","volume":"63","author":"Sekine","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.intimp.2023.110317_b0190","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1681\/ASN.2017010030","article-title":"A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"28","author":"Tomas","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0195","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.4049\/jimmunol.1003451","article-title":"Nephrotic syndrome and subepithelial deposits in a mouse model of immune-mediated anti-podocyte glomerulonephritis","volume":"187","author":"Meyer-Schwesinger","year":"2011","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MOT.0000000000000375","article-title":"The effect of chronic kidney disease on T cell alloimmunity","volume":"22","author":"Winterberg","year":"2017","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0205","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.kint.2018.06.025","article-title":"CD8+ T cells modulate autosomal dominant polycystic kidney disease progression","volume":"94","author":"Kleczko","year":"2018","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0210","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.immuni.2010.06.002","article-title":"Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways","volume":"32","author":"Lee","year":"2010","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0215","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000358588","article-title":"Skin-homing Th2\/Th22 cells in papuloerythroderma of Ofuji","volume":"228","author":"Teraki","year":"2014","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0220","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.intimp.2023.110317_b0225","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/08916934.2017.1385775","article-title":"Higher frequencies of circulating ICOS+, IL-21+ T follicular helper cells and plasma cells in patients with new-onset membranous nephropathy","volume":"50","author":"Zhang","year":"2017","journal-title":"Autoimmunity"},{"issue":"12","key":"10.1016\/j.intimp.2023.110317_b0230","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.4049\/jimmunol.1000202","article-title":"Signaling pathways in T follicular helper cells","volume":"184","author":"Rolf","year":"2010","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0235","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.4049\/jimmunol.1102948","article-title":"A regulatory role for IL-10 receptor signaling in development and B cell help of T follicular helper cells in mice","volume":"189","author":"Cai","year":"2012","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0240","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneph.2017.112","article-title":"T helper type 17 cells in immune-mediated glomerular disease","volume":"13","author":"Krebs","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0245","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/MNH.0000000000000269","article-title":"Current status of tolerance in kidney transplantation","volume":"25","author":"Chandran","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0250","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to rituximab in patients with membranous nephropathy: A prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2023.110317_b0255","doi-asserted-by":"crossref","first-page":"7638365","DOI":"10.1155\/2020\/7638365","article-title":"The potential role of regulatory B cells in idiopathic membranous nephropathy","volume":"2020","author":"Dong","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0260","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2010.02.018","article-title":"Clinical consequences of defects in B-cell development","volume":"125","author":"Vale","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0265","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5551\/jat.46284","article-title":"The release of monocyte-derived tissue factor-positive microparticles contributes to a hypercoagulable state in idiopathic membranous nephropathy","volume":"26","author":"Wang","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0270","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","article-title":"The anti-PLA2R antibody in membranous nephropathy: What we know and what remains a decade after its discovery","volume":"96","author":"van de Logt","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2023.110317_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109396","article-title":"Long non-coding RNAs: A double-edged sword in aging kidney and renal disease","volume":"337","author":"Wang","year":"2021","journal-title":"Chem. Biol. Interact."},{"issue":"7","key":"10.1016\/j.intimp.2023.110317_b0280","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0285","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110317_b0290","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0295","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1681\/ASN.2013020166","article-title":"Genetic variants in membranous nephropathy: Perhaps a perfect storm rather than a straightforward conformeropathy?","volume":"24","author":"Salant","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2023.110317_b0300","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lfs.2019.05.010","article-title":"Gene polymorphism and risk of idiopathic membranous nephropathy","volume":"229","author":"Liu","year":"2019","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.intimp.2023.110317_b0305","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1042\/CS20181110","article-title":"Lipid metabolism participates in human membranous nephropathy identified by whole-genome gene expression profiling","volume":"133","author":"Wu","year":"2019","journal-title":"Clin. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2023.110317_b0310","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0315","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1021\/acs.est.1c00552","article-title":"Reduced ambient PM2.5 was associated with a decreased risk of chronic kidney disease: A longitudinal cohort study","volume":"55","author":"Bo","year":"2021","journal-title":"Environ. Sci. Tech."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0320","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.kint.2016.01.012","article-title":"Podocyte injury and its consequences","volume":"89","author":"Nagata","year":"2016","journal-title":"Kidney. Int."},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0325","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2215\/CJN.03770412","article-title":"Onco-nephrology: Glomerular diseases with cancer","volume":"7","author":"Cambier","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0330","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: From models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0335","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrneph.2009.14","article-title":"Membranous nephropathy in systemic lupus erythematosus: A therapeutic enigma","volume":"5","author":"Mok","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0340","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5414\/CN107615","article-title":"Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy","volume":"78","author":"Li","year":"2012","journal-title":"Clin. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0345","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11255-021-02997-2","article-title":"Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy","volume":"54","author":"Ji","year":"2022","journal-title":"Int. Urol. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/09674845.2019.1666783","article-title":"Association of SNPs in PLA2R1 with idiopathic and secondary membranous nephropathy in two Chinese cohorts","volume":"77","author":"Tian","year":"2020","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2023.110317_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110289","article-title":"Transforming growth factor-\u03b2 signaling: From tissue fibrosis to therapeutic opportunities","volume":"369","author":"Ren","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.intimp.2023.110317_b0360","article-title":"TGF-\u03b2\/Smad signaling pathway in tubulointerstitial fibrosis","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110317_b0365","doi-asserted-by":"crossref","first-page":"800522","DOI":"10.3389\/fphar.2021.800522","article-title":"Shenkang injection and its three anthraquinones ameliorates renal fibrosis by simultaneous targeting I\u0199B\/NF-\u0199B and Keap1\/Nrf2 signaling pathways","volume":"12","author":"Luo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110317_b0370","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway as a potential therapeutic strategy in renal tubulointerstitial fibrosis","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110317_b0375","article-title":"Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt\/\u03b2-catenin signalling pathway","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0380","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s10157-010-0266-3","article-title":"Angioimmunoblastic T-cell lymphoma and membranous nephropathy: A still unreported association","volume":"14","author":"Togashi","year":"2010","journal-title":"Clin. Exp. Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10157-021-02147-z","article-title":"Evaluation of ultrastructural alterations of glomerular basement membrane and podocytes in glomeruli by low-vacuum scanning electron microscopy","volume":"26","author":"Lan","year":"2022","journal-title":"Clin. Exp. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0390","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin. Nephrol."},{"issue":"23","key":"10.1016\/j.intimp.2023.110317_b0395","first-page":"5415","article-title":"Value of immunofluorescence-mediated detection of Ig, C1q, C3, and FRA for the identification and diagnosis of atypical membranous nephropathy","volume":"21","author":"Wang","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0400","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0272-6386(12)80997-8","article-title":"IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies","volume":"23","author":"Haas","year":"1994","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0405","first-page":"536","article-title":"C4d as a diagnostic tool in membranous nephropathy","volume":"32","author":"Val-Bernal","year":"2012","journal-title":"Nefrologia"},{"issue":"11","key":"10.1016\/j.intimp.2023.110317_b0410","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/s41401-022-00914-6","article-title":"Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice","volume":"43","author":"Cao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0415","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41401-022-00947-x","article-title":"Integrative phosphatidylcholine metabolism through phospholipase A2 in rats with chronic kidney disease","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2023.110317_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101861","article-title":"Deciphering the role of lipoproteins and lipid metabolic alterations in ageing and ageing-associated renal fibrosis","volume":"85","author":"Liu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.intimp.2023.110317_b0425","doi-asserted-by":"crossref","first-page":"909491","DOI":"10.3389\/fphys.2022.909491","article-title":"Specific alterations of gut microbiota in patients with membranous nephropathy: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.intimp.2023.110317_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154763","article-title":"Moshen granule ameliorates membranous nephropathy by blocking intrarenal renin-angiotensin system signalling via the Wnt1\/\u03b2-catenin pathway","volume":"114","author":"Wang","year":"2023","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0435","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0440","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"issue":"9868","key":"10.1016\/j.intimp.2023.110317_b0445","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0450","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/kisup.2012.10","article-title":"KDIGO clinical practice guideline for glomerulonephritis foreword","volume":"2","author":"Eckardt","year":"2012","journal-title":"Kidney Int. Suppl."},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0455","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","article-title":"Does cyclophosphamide still play a role in glomerular diseases?","volume":"17","author":"Ponticelli","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0460","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/nep.12955","article-title":"Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in new-incident and relapsing primary membranous nephropathy","volume":"23","author":"Kanigicherla","year":"2018","journal-title":"Nephrology"},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0465","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1797.2010.01427.x","article-title":"Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: A single centre\u2019s retrospective study","volume":"16","author":"Yuan","year":"2011","journal-title":"Nephrology"},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0470","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jfma.2017.01.004","article-title":"Early initiation of immunosuppressive treatment in membranous nephropathy patients","volume":"116","author":"Chan","year":"2017","journal-title":"J. Formos. Med. Assoc."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0475","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1053\/j.ajkd.2013.12.001","article-title":"Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: Management of glomerulonephritis in adults","volume":"63","author":"Cybulsky","year":"2014","journal-title":"Am. J. Kidney Dis."},{"issue":"8","key":"10.1016\/j.intimp.2023.110317_b0480","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneph.2009.101","article-title":"Controversies in the treatment of idiopathic membranous nephropathy","volume":"5","author":"Waldman","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0485","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: Integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0490","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy","volume":"130","author":"Fervenza","year":"2015","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0495","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/0886022X.2017.1373130","article-title":"Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: Effectiveness and renal safety","volume":"39","author":"Yu","year":"2017","journal-title":"Ren. Fail."},{"issue":"9","key":"10.1016\/j.intimp.2023.110317_b0500","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00467-015-3109-3","article-title":"Response to cyclosporine in steroid-resistant nephrotic syndrome: Discontinuation is possible","volume":"30","author":"Klaassen","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.intimp.2023.110317_b0505","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2147\/DDDT.S204974","article-title":"Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population","volume":"13","author":"Lin","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0510","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1681\/ASN.V72290","article-title":"Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy","volume":"7","author":"Ambalavanan","year":"1996","journal-title":"J. Am. Soc. Nephrol"},{"issue":"9981","key":"10.1016\/j.intimp.2023.110317_b0515","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: Time for a shift in patient\u2019s care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0520","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","article-title":"Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide","volume":"2","author":"Ramachandran","year":"2017","journal-title":"Kidney Int. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0525","doi-asserted-by":"crossref","first-page":"C558","DOI":"10.1152\/ajpcell.00077.2008","article-title":"TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription","volume":"296","author":"Schl\u00f6ndorff","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0530","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","article-title":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials","volume":"16","author":"Qiu","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2023.110317_b0535","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","article-title":"Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome","volume":"27","author":"Wang","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0540","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/kjm2.12098","article-title":"Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study","volume":"35","author":"Zhang","year":"2019","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0545","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/ar3835","article-title":"Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus","volume":"14","author":"Eickenberg","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2023.110317_b0550","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0555","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12882-019-1539-z","article-title":"Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: A randomised controlled trial","volume":"20","author":"Nikolopoulou","year":"2019","journal-title":"BMC Nephrol."},{"issue":"11","key":"10.1016\/j.intimp.2023.110317_b0560","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: Mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2023.110317_b0565","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/nep.12143","article-title":"Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: A retrospective clinical study of efficacy and safety","volume":"18","author":"Yang","year":"2013","journal-title":"Nephrology"},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0570","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0090-1229(06)80011-5","article-title":"Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats","volume":"61","author":"Ogawa","year":"1991","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0575","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1440-1797.2006.00547.x","article-title":"Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy","volume":"11","author":"Lou","year":"2006","journal-title":"Nephrology"},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0580","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3109\/0886022X.2016.1172917","article-title":"Efficacy of leflunomide combined with prednisone in the treatment of refractory nephrotic syndrome","volume":"38","author":"Liu","year":"2016","journal-title":"Ren. Fail."},{"issue":"17","key":"10.1016\/j.intimp.2023.110317_b0585","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood-2014-07-585976","article-title":"Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers","volume":"124","author":"Wallin","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0590","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0595","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2023.110317_b0600","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0605","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110317_b0610","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am. J. Nephrol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110317_b0615","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent membranous nephropathy after kidney transplantation: Treatment and long-term implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0620","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: Cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.intimp.2023.110317_b0625","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/17512433.2016.1225497","article-title":"Pharmacological treatment of primary membranous nephropathy in 2016","volume":"9","author":"van de Logt","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110317_b0630","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus steroids plus cyclophosphamide in patients with primary membranous nephropathy: The STARMEN study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin. Kidney J."},{"issue":"12","key":"10.1016\/j.intimp.2023.110317_b0635","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029232","article-title":"Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: Protocol of a pilot randomised controlled trial","volume":"9","author":"Scolari","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0640","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.kint.2021.09.012","article-title":"The lupus nephritis management renaissance","volume":"101","author":"Mejia-Vilet","year":"2022","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0645","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00467-022-05670-7","article-title":"Recent advances in immunotherapies for lupus nephritis","volume":"38","author":"Kaneko","year":"2023","journal-title":"Pediatr. Nephrol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0650","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2015.33","article-title":"Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis","volume":"11","author":"Mohan","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"issue":"7300","key":"10.1016\/j.intimp.2023.110317_b0655","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature09102","article-title":"TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus","volume":"465","author":"Guiducci","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.intimp.2023.110317_b0660","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"24","key":"10.1016\/j.intimp.2023.110317_b0665","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.3390\/ijms20246199","article-title":"The role of IgA in the pathogenesis of IgA nephropathy","volume":"20","author":"Per\u0161e","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2023.110317_b0670","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2014.92","article-title":"Pathology of IgA nephropathy","volume":"10","author":"Roberts","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0675","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00011-016-0962-x","article-title":"Immunoglobulin A nephropathy: A pathophysiology view","volume":"65","author":"Fabiano","year":"2016","journal-title":"Inflamm. Res."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.110317_b0680","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000481636","article-title":"Immunoglobulin A nephropathy: Advances in understanding of pathogenesis and treatment","volume":"47","author":"Lafayette","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.intimp.2023.110317_b0685","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-med-041811-142014","article-title":"Pathogenesis of immunoglobulin A nephropathy: Recent insight from genetic studies","volume":"64","author":"Kiryluk","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0690","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.trsl.2015.02.007","article-title":"Immunoglobulin A nephropathy: Current progress and future directions","volume":"166","author":"Zhang","year":"2015","journal-title":"Transl. Res."},{"issue":"7","key":"10.1016\/j.intimp.2023.110317_b0695","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11926-020-00906-7","article-title":"An update on the diagnosis and management of lupus nephritis","volume":"22","author":"Kostopoulou","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"issue":"11","key":"10.1016\/j.intimp.2023.110317_b0700","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/17512433.2022.2138340","article-title":"Novel and emerging treatment strategies for lupus nephritis","volume":"15","author":"Yap","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110317_b0705","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","article-title":"Current treatment of IgA nephropathy","volume":"43","author":"Floege","year":"2021","journal-title":"Semin. Immunopathol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0710","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cyto.2014.12.027","article-title":"Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity","volume":"72","author":"Talaat","year":"2015","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0715","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000353102","article-title":"Various roles of Th cytokine mRNA expression in different forms of glomerulonephritis","volume":"38","author":"Ifuku","year":"2013","journal-title":"Am. J. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110317_b0720","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/1440-1681.12555","article-title":"Increased ratio of ICOS+\/PD-1+ follicular helper T cells positively correlates with the development of human idiopathic membranous nephropathy","volume":"43","author":"Shi","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0725","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110317_b0730","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nri3523","article-title":"The immune system and kidney disease: Basic concepts and clinical implications","volume":"13","author":"Kurts","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110317_b0735","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.intimp.2023.110317_b0740","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10157-016-1340-2","article-title":"Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome","volume":"21","author":"Saito","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110317_b0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nep.12161","article-title":"Leflunomide in idiopathic membranous nephropathy: A new immunosuppressive with promising treatment potential","volume":"19","author":"Chen","year":"2014","journal-title":"Nephrology"},{"issue":"9","key":"10.1016\/j.intimp.2023.110317_b0750","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: Time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat. Rev. Nephrol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:13:53Z","timestamp":1761588833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923006409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":150,"alternative-id":["S1567576923006409"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110317","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Membranous nephropathy: Mechanistic insights and therapeutic perspectives","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110317"}}